Technology evaluation: R-1549, Antisoma/Roche.
R-1549 (formerly known as pemtumomab), a murine monoclonal antibody (HMFG1) specific for the cancer antigen PEM and radiolabeled with yttrium-90, is under development by Antisoma and Roche as a potential treatment for ovarian and gastric cancer. In July 2003, enrollment for a phase III trial in ovarian cancer was completed.